2000 OPEN FORUM Abstracts
Therapeutic Rationale for Single Isomer Beta Agonists
Dean A. Handley Senior Director, Scientific Affairs; Sepracor, Inc
I will address the mystical world of racemic drugs, many of the progressive outcomes in the area of single isomer biology (i.e.: fluoxetine), new developments is single isomer therapy (i.e.: atorvastatin), and the progress in single isomer third generation
I will define the concept of a racemic drug, what respiratory drugs are racemic and why they were marketed as mixtures. We will also recognize the current concerns with use of racemic beta agonists; the most widely used class of asthma drugs, in terms of adverse events and appraise the development of the new class of isomerically pure respiratory drugs.